Certara.AI
Contact for pricing
Regulatory Status Disclosed
Overview
Certara.AI is an artificial intelligence platform developed by Certara, designed for applications within the life sciences sector. It is intended for use by pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) involved in drug discovery and development.
- The platform aims to integrate AI capabilities into various stages of the drug development lifecycle.
- It supports workflows related to regulatory writing through its CoAuthor™ GenAI component, which provides generative AI, templates, and structured content.
- Certara.AI is positioned to assist in enhancing scientific discovery by leveraging chemical and biological intelligence, as indicated by its integration with Chemaxon®.
- The tool is part of a broader suite of Certara software solutions that focus on areas such as PK/PD analysis, data standardization, and biosimulation, suggesting its role in augmenting these existing processes.
The platform’s utility is primarily within research and development settings, supporting scientists and regulatory professionals in managing and analyzing complex data throughout the drug development pipeline.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Specialized AI platform for life sciences
- Purpose-built GPT models trained on biomedical data
- AI model agnostic (deploy tailored off-the-shelf or custom models)
- Real-time data access through a flexible data fabric
- Scalable and adaptable architecture
- Secure cloud solution (ISO27001 certified) or on-premise deployment
- No-code life science application suite
- Customizable and scalable API
- Automated report reviews and literature screenings
- Unstructured data analysis
Use Cases
- Accelerating submission timelines and creating dossier drafts
- Transforming report review and literature screening
- Revolutionizing clinical outcomes analysis (CODEX platform)
- Unlocking real-time market intelligence (Signal platform)
- Enhancing drug discovery workflows with D360u2122
- Streamlining clinical trial analytics with unstructured data analysis
What Physicians Need to Know
Molecule Screening Capability
Leverages specialized GPT models and biosimulation to prioritize new molecules, evaluate ADMET properties, and refine early-stage candidates.
Literature Mining
Automates the screening of large volumes of unstructured biomedical literature, reducing manual data extraction times from days to minutes.
Target Identification
Integrates mechanistic modeling and Quantitative Systems Pharmacology (QSP) to explore early discovery hypotheses and identify biological targets.
Collaboration Features
Features real-time version tracking and shared environments (such as IQ Explore and IQ Design) to streamline collaboration across scientific teams.
Publication Support
Accelerates medical writing and regulatory drafting through CoAuthor, a GPT-powered tool designed to generate compliant, structured reports.
Physician Tip
While Certara.AI is primarily designed for pharmaceutical R&D, clinical researchers can leverage its specialized GPT models to quickly synthesize complex preclinical data, optimize dosing strategies via biosimulation, and accelerate the drafting of clinical trial protocols or regulatory-ready evidence.
Certara.AI securely integrates with proprietary organizational data systems and connects directly with Certara's broader software suite (including Phoenix, Pinnacle 21, and D360), as well as frontier AI tools like the NVIDIA BioNeMo Agent Toolkit for autonomous scientific workflows.
Details
| Category | Drug Discovery & Research, Pharmacology & Dosing AI |
| Pricing | Contact for pricing |
| Deployment | Cloud (ISO27001 certified) or on-premise |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status | Not applicable AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Laboratory Medicine, Oncology, Pathology |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Certara.AI
Press & Coverage
Certara Press Release
Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit
Certara has partnered with NVIDIA to integrate the BioNeMo Agent Toolkit into its open, integrated AI platform, enabling specialized AI agents to autonomously generate drug development insights.
2026-07
Reuters
Certara partners with Nvidia to integrate AI agents into drug development platform
This media coverage details Certara's landmark collaboration with NVIDIA to embed agentic AI frameworks into its biosimulation and regulatory workflows to speed up drug discovery.
2026-07
Bio-IT World & Expo
Applying AI-Driven Biosimulation to Drug Discovery
Leif Pedersen, President of Certara, presents at Bio-IT World on pushing mechanistic modeling and agentic AI upstream into drug discovery to reduce high Phase I failure rates.
2026-06
Certara Press Release
Phoenixu00ae PK/PD Software now Includes Generative AI pharmacokinetic (PK) Reports
Certara announced the release of AI PK Reports, an AI-powered module within Phoenix Cloud that leverages generative AI to convert tables, figures, and listings into draft reports in minutes.
2026-01
Certara Press Release
Certara Expands Biosimulation Market with AI-Driven QSP Platform
Certara launched Certara IQ, a scalable, AI-powered Quantitative Systems Pharmacology (QSP) solution designed to streamline drug discovery and enhance model reproducibility.
2025-10
Certara Press Release
Certara Joins Veeva AI Partner Program to Simplify and Expedite Regulatory Submissions for Life Sciences
Certara announced an integration with Veeva RIM to simplify digital data flows and enhance document automation using CoAuthor, Certara's generative AI solution.
2025-10
Bioanalysis Zone
Certara launches TFL Studio to accelerate scientific workflows
This article highlights the launch of Certara's TFL Studio, a cloud-native module that automates data presentation tasks and integrates with generative AI tools to draft PK reports.
2025-11
Certara Press Release
Certara Launches Next Generation CoAuthoru2122 Generative AI Regulatory Writing Software
Certara introduced CoAuthor, a next-generation generative AI software designed to help medical writers create consistent, reproducible regulatory content and reduce draft times.
2024-06
Videos
Product demos, reviews, and walkthroughs for Certara.AI.
Certara.AI
Certara
How Will Generative AI Take Your Regulatory and Medical Writing Program to the Next Level? - Recap
Certara
Certara (CERT) u2013 Accelerating Medicines with Biosimulation
Certara
Certara Next Generation Data Repository Webinar Preview
Bio ITWorld
Certara RsNLME capability and its use by Mr. Takanori Ogawa at Global Virtual Healthcare Summit 2022
AKT Health
Certara Evidence and Access
Certara
Frequently Asked Questions
Certara.AI integrates biosimulation models, such as Physiologically Based Pharmacokinetics (PBPK) and Quantitative Systems Pharmacology (QSP), with agentic AI frameworks to predict drug behavior upstream [1.1.1]. This allows researchers to evaluate ADMET properties, simulate patient scenarios, and explore early discovery hypotheses to reduce Phase I failure rates. By automating complex modeling workflows, it helps scientific teams accelerate candidate selection and optimize dosing strategies early in development.
Certara.AI is built as a secure, enterprise-grade platform specifically designed to handle sensitive life sciences data without exposing proprietary IP to public models. It utilizes closed, secure environments and specialized GPT models trained specifically on biomedical and regulatory data rather than broad public datasets. This ensures that the generation of regulatory-ready evidence and clinical insights complies with stringent pharmaceutical industry standards.
Primary alternatives include specialized AI platforms like Schrodinger (for molecular modeling and physics-based simulations), Insilico Medicine (for generative chemistry and target discovery), and Exscientia. While these platforms focus heavily on de novo molecular design, Certara.AI differentiates itself by uniquely combining generative AI with established biosimulation, QSP modeling, and regulatory writing capabilities.
Certara.AI does not have a public, flat-rate pricing model; instead, it uses customized enterprise licensing tailored to an organization's scale, user count, and specific module needs. Pricing typically depends on whether a company is integrating specific biosimulation software, regulatory writing tools, or utilizing their advanced NVIDIA BioNeMo agentic frameworks. Interested organizations must contact Certara directly for a tailored commercial quote and pilot program options.
While highly advanced, Certara.AI's predictive accuracy is ultimately dependent on the quality and volume of the underlying biological and clinical datasets provided to it. Additionally, because it relies on complex agentic AI and biosimulation, there is still a learning curve for research teams to properly configure and interpret the models. It is designed to augment, not replace, human scientific expertise, meaning a 'scientist-in-the-loop' is always required to validate AI-generated hypotheses.
The platform utilizes advanced generative AI and large language models (LLMs) specifically fine-tuned for the life sciences to ingest, structure, and analyze massive volumes of unstructured data. It can rapidly synthesize clinical trial outcomes, medical literature, and internal datasets to assist in trial design and meta-analyses. This significantly reduces the manual labor required by medical writers and clinical investigators to compile regulatory-ready documents.
Suggest an Edit →
| Last Verified: 2026-07-09 | First Added: 2026-07-09
Investors who backed Certara.AI
Funded through the company that built this tool.
